| Company/Division name | NurExone Biologic Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Israel |
| City reshored to: | Indianapolis |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | regenerative aesthetic therapeutics |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Infrastructure |
